目的 分析津力达颗粒联合洛塞那肽治疗2型糖尿病的临床疗效。方法 选取2022年8月—2023年7月淮南东方医院集团总医院收治的96例2型糖尿病患者，按随机数字表法将所有患者分为对照组和治疗组，每组各48例。对照组腹部皮下注射聚乙二醇洛塞那肽注射液，0.1 mg/次，1次/周。治疗组在对照组治疗基础上口服津力达颗粒，1袋/次，3次/d。两组疗程均为8周。观察两组的临床疗效，比较治疗前后血糖指标、全血中性粒细胞与淋巴细胞比值（NLR）和血清C反应蛋白（CRP）、C肽（CP）水平变化情况。并统计两组不良反应情况。结果 治疗后，治疗组总有效率是95.83%，显著高于对照组的83.33%（P＜0.05）。治疗后，两组餐后2 h血糖（2 h PG）、空腹血糖（FPG）、糖化血红蛋白（HbA1c）均显著降低（P＜0.05）；治疗后，治疗组血糖指标低于对照组（P＜0.05）。治疗后，两组全血NLR和血清CRP水平均显著下降，而血清CP水平均显著上升（P＜0.05）；治疗后，治疗组全血NLR和血清CRP低于对照组，CP水平高于对照组（P＜0.05）。治疗组和对照组的不良反应发生率分别是6.25%、4.17%，两组比较差异无统计学意义。结论 津力达颗粒联合洛塞那肽治疗2型糖尿病具有较佳的安全性及整体疗效，能有效降低血糖，减轻机体炎症损伤，改善胰岛功能。

Objective To analyze the clinical efficacy of Jinlida Granules combined with loxenatide in treatment of type 2 diabetes. Methods A total of 96 patients with type 2 diabetes admitted to Huainan Oriental Hospital Group General Hospital from August 2022 to July 2023 were selected and divided into control group and treatment group according to random number table method, with 48 patients in each group. Patients in the control group were sc administered with Polyethylene Glycol Loxenatide Injection, 0.1 mg/time, once a week. Patients in the treatment group were po administered with Jinlida Granules on the basis of the control group, 1 bag/time, 3 times daily. The treatment course of both groups was 8 weeks. The clinical effects of the two groups were observed, and the changes of blood glucose index, whole blood neutrophil to lymphocyte ratio (NLR), serum C-reactive protein (CRP) and C-peptide (CP) levels before and after treatment were compared. The adverse reactions of the two groups were analyzed. Results After treatment, the total effective rate of the treatment group was 95.83%, which was significantly higher than that of the control group (83.33%, P < 0.05). After treatment, 2 h postprandial blood glucose (2 h PG), fasting blood glucose (FPG) and glycosylated hemoglobin (HbA1c) in both groups were significantly decreased (P < 0.05). After treatment, the blood glucose index of the treatment group was lower than that of the control group (P < 0.05). After treatment, whole blood NLR and serum CRP levels were significantly decreased, while serum CP levels were significantly increased in both groups (P < 0.05). After treatment, whole blood NLR and serum CRP in the treatment group were lower than those in the control group, CP level was higher than that in the control group (P < 0.05). The incidence of adverse reactions in the treatment group and the control group was 6.25% and 4.17%, respectively, and there was no statistical significance between the two groups. Conclusion Jinlida Granules combined with loxenatide has better safety and overall efficacy in treatment of type 2 diabetes, and can effectively reduce blood sugar, alleviate inflammatory damage, and improve islet function.

R977

上海市科委“长三角科技创新共同体领域项目合作协议”项目(22002400600)